Remogliflozin etabonate (RE), the prodrug of remogliflozin, is an inhibitor of the sodium glucose-dependent renal transporter 2 (SGLT2), enabling urinary glucose excretion to reduce hyperglycemia for the treatment of type 2 diabetes. Renal function declines more rapidly in patients with type 2 diabetes, making it difficult or unsafe to continue on some antidiabetic therapeutics. In an initial effort to understand the potential utility of RE in patients with renal impairment, the pharmacodynamics and pharmacokinetics of RE were evaluated in a single oral dose (250 mg) in patients with renal impairment as compared with control subjects. As shown by pharmacodynamic measurements of urinary glucose excretion, there was no clinically significant reduction in the ability of remogliflozin to inhibit SGLT2. In addition, there were no significant changes in area under the curve (from 0 to infinity) or half-life of remogliflozin, suggesting renal impairment does not alter the pharmacokinetics of remogliflozin. In contrast to other SGLT2 inhibitors which accumulate in patients with renal impairment, adjustment of the dosage of RE in subjects with mild or moderate renal impairment is not indicated based on the observations in this study.
Introduction
The prevalence of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide. Diabetes is the leading cause of chronic kidney disease (CKD) in the United States, with 22% of the U.S. population suffering from this disease. Moreover, diabetes accounts for 43.5% of prevalent kidney failure, increasing to 61% in patients over the age of 65 (Bailey et al., 2014) .
The kidney plays a major role in the clearance of drugs in general, and of glucose-lowering agents used for T2DM in particular (Sun et al., 2006) . Therefore, the management of glycemia in patients with diabetes and CKD is quite challenging, and the questions of which hypoglycemic agents to use in T2DM subjects with CKD and their dosing parameters are of major practical importance.
In addition to the mode of action of glucose-lowering agents, renal function should also be taken into account by the physician. Indeed, renal impairment may deeply impact the pharmacokinetics of these agents and thereby influence choices, dosing, and monitoring of these drugs according to the reduction of glomerular filtration rate (Snyder and Berns, 2004; Cavanaugh, 2007; Haneda and Morikawa, 2009 ). The situation is even more complex in the elderly population, where renal impairment and polymedication are more common (Ferrannini et al., 2013) . Sodium/glucose cotransporters (SGLTs) are expressed in the absorptive epithelia of the gastrointestinal tract (SGLT1) and renal tubules (SGLT1 and SGLT2). SGLT2 is primarily expressed on the luminal side of the S1 segment of the renal proximal tubule and is responsible for approximately 90% of renal glucose reabsorption, whereas renal SGLT1 is located in the distal S3 segment and is responsible for the remaining 10% of renal glucose reabsorption (Kanai et al., 1994; Tonelli et al., 2006; Chao and Henry, 2010; DeFronzo et al., 2012) . Thus, SGLT2 is the primary pathway for renal glucose reabsorption. Once reabsorbed across the renal epithelium, glucose is transported to the blood by facilitated diffusion through the GLUT2 transporter. The uptake of glucose in the proximal tubules is highly efficient, resulting in complete reabsorption of glucose in subjects with plasma glucose concentrations below 180 mg/dl. Inhibitors of SGLT2 have acute and chronic effects on plasma glucose concentration, providing therapeutic benefits to patients with T2DM (Wright et al., 2011) . A number of SGLT2 inhibitors, such as dapagliflozin, canagliflozin, and ipragliflozin, have altered pharmacokinetic and/or pharmacodynamic properties when administered to subjects with mild This work was supported by GlaxoSmithKline. dx.doi.org/10.1124/dmd.114.062828.
ABBREVIATIONS: AE, adverse event; AUC, area under the curve; AUC 0-' , area under the curve from 0 to infinity; CI, confidence interval; CKD, chronic kidney disease; CLcr, creatinine clearance; %CV, coefficient of variation; GSK189074, 5-methyl or moderate renal impairment (Isaji, 2007; Food and Drug Administration, 2011, 2013; Yale et al., 2013; Macha et al., 2014) . Remogliflozin etabonate (RE) is a SGLT2 inhibitor that causes a concentration-dependent increase in urine glucose excretion Kapur et al., 2013) . RE reduces postprandial glucose excursions, hemoglobin A1c, and fasting plasma glucose without inducing hypoglycemia in subjects with T2DM (Dobbins et al., 2012; Sykes et al., 2015a,b) . RE is an O-linked glycoside, whereas other SGLT2 inhibitors are C-linked glycosides. RE is the ester prodrug of remogliflozin, a selective and nanomolar potent inhibitor of SGLT2. In a pharmacokinetics (PK)/pharmacodynamics study with healthy volunteers and type 2 diabetes patients, RE was generally well tolerated; there were no serious adverse events.
RE is rapidly absorbed and converted to the active entity remogliflozin [time to maximum plasma concentration (C max , T max ) approximately 1 hour] by esterases present in the gastrointestinal tract . Generally, exposure to remogliflozin is proportional to the administered dose. Remogliflozin is extensively metabolized to several metabolites (Fujimori et al., 2008) , and is rapidly eliminated [mean plasma half-life (t 1/2 ) = 120 minutes) independent of dose administered . Multiple cytochrome P450 enzymes, glucuronidases and non-cytochrome P450 enzymes (e.g., glucosidases) are involved in the majority of remogliflozin clearance (Sigafoos et al., 2012) . Two active metabolites, GSK279782
, made up the majority of the glucuronidated species, with GSK1997711 being the most abundant. Products of remogliflozin metabolism are eliminated primarily via renal excretion, with 92.8% of the dose recovered in the urine. Because of these considerations, this study was designed to evaluate safety, PK, and pharmacodynamics of RE in subjects with mild and moderate renal impairment. We observed that the pharmacokinetics of remogliflozin and its metabolites are not significantly altered in subjects with either mild or moderate renal impairment, suggesting that dose alteration for renal-impaired type 2 diabetes patients may not be necessary.
Materials and Methods
This clinical study was conducted in accordance with Good Clinical Practices, subject privacy requirements, and the guiding principles of the Declaration of Helsinki. Written informed consent was obtained from each subject prior to any study-specific procedure. The ClinicalTrials.gov identifier is NCT00501462.
Study Design. This phase 1, open-label, single-dose, parallel-group study was designed to characterize the pharmacokinetics of a single 250-mg oral dose of RE [GSK189075, 5-methyl- 
Previous studies have demonstrated that 250 mg once a day is a sufficient dose to significantly inhibit SGLT2 and provide therapeutic benefit in subjects with T2DM (Sykes et al., 2015a,b) . Subjects with normal renal function were recruited to match subjects with chronic renal impairment for gender, age (65 years), and body mass index (615%). Subjects with normal renal function [creatinine clearance (CLcr) . 80 ml/min] were considered as a match for subjects with either mild renal impairment (CLcr between 50 and 80 ml/min) or moderate renal impairment (CLcr between 30 and 49 ml/min). Subjects with T2DM were included if they met all of the inclusion/exclusion criteria. Subjects were allowed necessary medications for management of their medical conditions [for example, antihypertensives and antidiabetic medications (except a Includes three subjects who were considered matches for both mild and moderate impaired subjects.
metformin)], provided they met the definition of a stable regimen and were medically able to withhold their medications starting at a minimum of 8 hours before study drug administration. Medications were withheld throughout the PK sampling period. Patients with renal impairment were required to be clinically stable as assessed by the investigators. Stable renal function was defined as #25% difference in estimated CLcr during the 30 days prior to study drug administration. Renal function was based on the Cockcroft-Gault equation using serum creatinine values obtained on two occasions separated by at least 2 weeks within the screening period. Each serum creatinine collection for estimation of CLcr was drawn within the 30-day period prior to study drug administration.
Treatment Procedures. Subjects arrived at the clinic a day before (day 21) drug administration, and urine samples were collected. On day 1, subjects received a single oral dose of 250 mg of remogliflozin. Fifteen minutes later, subjects were given a breakfast meal. This was followed by lunch 6 hours later and dinner 12 hours after drug administration.
All meals were standardized with respect to nutrient and caloric content. Blood samples were collected for pharmacokinetic analysis of drug and metabolite concentrations starting immediately prior to study drug administration and following dosing at scheduled times over 24 hours.
Urine was collected for analysis of volume, glucose, creatinine, and electrolyte (Na, Cl, K, Mg, and Ca) concentrations and osmolality over intervals beginning 24 hours before and for 24 hours following dosing. Serum glucose and creatinine were collected for calculation of the percentage of glucose filtered. Urine collected after dosing was stored for analysis of remogliflozin and GSK279782.
Among the 12 subjects with normal renal function, eight were used as the matched normal for mild renal impairment, and seven were used as the matched normal for moderate renal impairment. Thus, three subjects (subject numbers 53002, 53046, and 53087) with normal renal function were included in both normal matched groups. The CLcr values determined on day 21 and day 1 based on actual measurements of 0-to 24-hour urinary creatinine excretion for subjects with renal impairment and their matched normal subjects are summarized in Table 1 , and demographics are summarized in Table 2 .
Statistical Methods. Descriptive statistics, including arithmetic mean and associated 95% confidence interval (CI), standard deviation (SD), minimum, median, maximum, and coefficient of variation (%CV), were provided for all plasma and urine PK and pharmacodynamic parameters. For most plasma PK parameter analytes, the geometric mean and the associated 95% CI were calculated by renal function group. For T max , only median, minimum, and maximum values were provided by renal function group.
For summaries of log-transformed variables, the between-subject %CV was calculated as %CVb = 100 * square root (e SD**2 -1), with the SD. of the logtransformed data. For summaries of untransformed variables, the betweensubject %CV was calculated as %CVb = 100 * (SD/mean), with the SD and mean of the untransformed data.
The effect of renal impairment on PK of RE and its metabolites in urine and plasma was evaluated by descriptively comparing PK parameters of subjects with mild or moderate renal impairment to their matched control subjects with normal renal function.
Following natural log transformation, plasma C max and area under the curve from 0 to infinity (AUC 0-' ) were analyzed separately by analysis of variance, fitting a single term for renal function group. Point estimates and associated 90% CIs for the differences in least-squares means were constructed using the residual variance. Point and confidence limits estimates for the differences in least-squares means were then exponentially back transformed to construct the point estimate and 90% CI for the ratios of the geometric least-squares means for mild:matched normal and moderate:matched normal, respectively.
Model and distributional assumptions underlying each analysis were assessed by visual inspection of residual plots. In addition, exploratory sensitivity mixedmodel analyses were performed to evaluate the relationship of GSK189074 C max and AUC from 0 to 24 hours as a function of the measured day 1 CLcr while controlling for age, sex, and race. The PK parameters were log transformed prior 
Results
Safety and Adverse Events. Nine subjects reported a total of 18 adverse events (AEs), regardless of causality. All were mild except for one headache unrelated to the study drug. Four AEs were drug-related, and symptoms consisted of dizziness, dysgeusia, presyncope, and nausea. The only AE that was reported by more than one subject in any specific group was mild erythema, unrelated to the study drug. No action was taken due to any drug-related AEs, and all AEs were resolved by the end of the study. With respect to specific markers of renal toxicity, there were no changes in urinary microalbumin or electrolyte composition or concentration in response to remogliflozin etabonate dosing (not shown). Additionally, 12-week studies dosing remogliflozin etabonate up to 1000 mg twice daily did not indicate any changes in renal capacity or function (Sykes et al., 2015a,b) .
Plasma Pharmacokinetics. Plasma concentration-time data for the prodrug and its metabolites were available from 12 subjects with mild renal impairment, 7 subjects with moderate renal impairment, and 12 subjects with normal renal function. A few of the normal match subjects were used in both comparisons. In general, RE (prodrug) concentrations were measurable from 0.25 hours postdose and up to 3-4 hours postdose in all subjects. Plasma concentrations of the remogliflozin (active entity) appeared rapidly and were measurable starting at 0.25 hours postdose in almost all subjects, lasting up to at least 12-16 hours in all subjects (Fig. 1) .
Based on the geometric mean values for remogliflozin, there was an approximate 10% increase in AUC and t 1/2 of remogliflozin, and slight to no increase in C max of remogliflozin in subjects with renal impairment (Table 3 ). There was essentially no difference in the unbound fraction of remogliflozin in plasma among the four renal function groups. Remogliflozin was present in plasma at 60-to 80-fold higher concentrations than the parent prodrug, and there was no change in the AUC ratio, metabolite/parent, between groups. These data indicated no alterations in the metabolic formation or elimination of remogliflozin in renal impairment. In all groups, the renal clearance of remogliflozin was a relatively small fraction of the estimated total oral clearance.
Plasma concentrations of GSK279782 and GSK333081 (major metabolites of RE) also appeared rapidly in plasma. These metabolites were measurable as early as 0.25 hours postdose in the majority of subjects and at 0.5 hours postdose in all subjects. GSK279782 continued to be measurable up to 16 hours postdose in subjects with normal renal function or mild renal impairment, but up to 24 hours AUC(0-t), area under curve fro 0 to last measurable concentration; AUC 0-',u , area under curve from 0 to infinity corrected for unbound fraction; CLr, renal clearance; CLr,u, renal clearance corrected for unbound fraction. postdose in several subjects with moderate renal impairment. GSK333081 continued to be measurable up to 12 hours postdose in subjects with normal renal function, up to 12-16 hours in subjects with mild renal impairment, and up to 16 hours in subjects with moderate renal impairment.
The statistical results of the observed geometric mean ratios of the various renal function groups' PK parameters are presented in Table 4 . Sensitivity analyses explored the impact of measured day 1 CLcr on remogliflozin (GSK189074) C max and AUC 0-' . Scatter plots of AUC 0-' and C max show little association of CLcr on exposure (Figs. 2 and 3) .
Urine Pharmacokinetics. The cumulative amount of intact remogliflozin and GSK279782 excreted over the 0-to 24-hour postdose urine collection interval and percentage of RE dose recovered in urine as remogliflozin or GSK279782 over the 24-hour collection interval, and the renal clearance of each metabolite for each renal function group are summarized in Table 5 . The percentage of dose recovered as remogliflozin or GSK279782 in urine was reduced in subjects with renal impairment. Similarly, renal clearance values, total and unbound, for each analyte were also largely reduced in subjects with renal impairment, and the extent of reduction was greater in subjects with moderate renal impairment.
Pharmacodynamic/Pharmacokinetic Results. Figure 4 shows scatter plots of the percentage of filtered glucose as a function of creatinine clearance from 0 to 6 hours for day -1 (predose) and day 1.
Consistent with inhibition of SGLT2 by RE, the amount of glucose excreted in the urine was significantly increased on day 1, compared with day 21 (mild: 12.4-fold increase; mild match: 36.3-fold increase; moderate: 4.7-fold increase; moderate match: 30.4-fold increase). This was clearly demonstrated across all subjects and levels of renal impairment. With the addition of a regression line with a near-zero slope for day 1, no trends suggesting differences in filtered glucose were evident across the levels of renal impairment on day 1 (Fig. 4) .
The amount of urine glucose excreted during the first 6 hours after dosing demonstrated a trend of increasing amounts in subjects with higher creatinine clearance levels. Variability levels appeared higher at the lower end of the urine creatinine clearance (Fig. 5) .
Although the slope of the regression line (amount = 37.78 mmol + 0.521 mmol*min/ml*CLcr) is statistically significant (P , 0.001), the slope shows a modest increase. For instance, an increase from moderately impaired (,50 ml/min) to normal (.80 ml/min) in urine creatinine clearance would suggest an increase of approximately 16 mmoles over 6 hours. Clearly, more renal filtration provides better efficacy for SGLT2 inhibitors in general.
Discussion
Following oral administration, RE is rapidly and extensively converted to remogliflozin, which then undergoes considerable metabolism and rapid clearance. As reported in prior studies, only 7.9% of the dose recovered in urine was remogliflozin (Fujimori et al., 2008) . A [
14 C]prodrug mass-balance study showed that metabolites accounted for more than 76% of dose recovery. Overall, 93% of the radiolabeled dose is recovered in urine (of which approximately 90% has been identified as remogliflozin or metabolites). Based on these previous studies, it was anticipated that remogliflozin would not accumulate in renal impaired subjects, nor would a loss of SGLT2 inhibitory activity be observed. Consistent with this hypothesis, the pharmacokinetics of remogliflozin etabonate and its metabolites following a single oral dose of 250 mg of RE in subjects with mild or moderate renal impairment showed only minimal (#10%) increases in AUCs and/or t 1/2 of remogliflozin. Moreover, pharmacodynamic measurements of urine glucose excretion indicated no alteration of the ability of remogliflozin to inhibit SGLT2 in these subjects.
The PK results of this study indicate that no dose adjustment of RE in subjects with mild or moderate renal impairment would be necessary. The importance of this finding is that at least three SGLT2 Fig. 3 . Plot of remogliflozin (GSK189074) C max versus day 1 CLcr (ml/min). inhibitors-canagliflozin, dapagliflozin, and empagliflozin-have presented with significant plasma accumulation in mild and moderately renal-impaired subjects (Food and Drug Administration, 2011, 2013; Macha et al., 2014) . Interestingly, although the plasma concentrations of these compounds were elevated, there was a corresponding decrease in urinary glucose excretion. Whether this is directly coupled to the decreased filtration rate in these renal-compromised subjects or is an effect of the accumulation of compound/metabolites is unclear.
Remogliflozin is a competitive inhibitor of SGLT2 with respect to glucose (Fujimori et al., 2008) , which likely ameliorates any potential drug-drug interaction possibilities for patients taking concurrent medications. In fact, few compounds appear to interfere with the ability of remogliflozin to inhibit SGLT2 or its metabolism (Sigafoos et al., 2012) . With respect to pharmacodynamic parameters, the amount of glucose excreted in the urine was significantly increased following dosing with RE in all groups, as anticipated. Urine glucose excretion was higher in the respective matched groups compared with the mild and moderate impairment groups on day 1. Subjects with diabetes mellitus were not excluded from this study, and several subjects with high serum glucose concentrations, particularly in the moderate impairment group, contributed to the variability observed in urine glucose excretion on both the baseline and treatment days. The percentage of filtered glucose excreted was consistent across the renal function groups following dosing with RE, despite a lower filtration rate in the impaired groups. This observation suggests that, although less glucose may be delivered to the site of action (SGLT2 in the kidney), glucose reabsorption is inhibited to the same degree in subjects with renal impairment when RE is administered. The effect of RE in severe renal impairment will need to be examined, but the mechanism of action for glucose lowering suggests limited efficacy in these subjects. This is in contrast to canagliflozin, which shows significant decreases in UGE as the percentage of filtered glucose in renal impaired subjects (Yale et al., 2013) .
With regard to the metabolites of remogliflozin, the mean plasma AUCs were increased by about 30-50% and 30-70% for GSK279782 and GSK333081, respectively, with similar increases in unbound AUCs, in subjects with mild to moderate renal impairment. The greater increases in AUCs for these two metabolites, as compared with remogliflozin, are consistent with the greater involvement of renal excretion of these polar metabolites as the elimination pathway. However, both of these metabolites represent a small percentage of the total remogliflozin amount (,5% combined). Therefore, the small increases in AUC for GSK279782 and GSK333081 are likely of little consequence in renal impairment.
In summary, mild and moderate renal impairment does not result in clinically meaningful effects on the plasma exposure or plasma halflives of RE and remogliflozin, consistent with the known extensive metabolism as the primary elimination pathway for these compounds. The amount of glucose excreted in the urine was modestly higher as creatinine clearance increased. However, the percentage of filtered glucose excreted was unchanged across the different levels of renal impairment. Based on the results of this study, no dose adjustment of RE is recommended in subjects with mild or moderate renal impairment. 
